Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

计划入组 300 人 · 首次发布于 2023 年 10 月 4 日

Teverelix Evaluated in Advanced Prostate Cancer

计划入组 50 人 · 首次发布于 2021 年 1 月 5 日

Personalizing Docetaxel Dosing in Advanced Prostate Cancer

计划入组 32 人 · 首次发布于 2021 年 4 月 1 日

anti-PAP CAR T-cell therapy (advanced prostate cancer)

anti-PSMA CAR T-cell therapy

Triptorelin(Decapeptyl, Trelstar, Triptodur)

C₆₄H₈₂N₁₈O₁₃ · Rx

PROSTATE LASER CENTER, PLLC

United States

NEW YORK PROSTATE INSTITUTE

United States

ADVANCED BIONICS

France

Foresee Pharmaceuticals Seeks FDA Approval for 3-Month Leuprolide Mesylate in Advanced Prostate Cancer

AbbVie's LUPRON DEPOT Receives Health Canada Approval for New 6-Month Dosing Option in Advanced Prostate Cancer

Lutetium-177-PSMA-617 Shows Promise in Advanced Prostate Cancer Treatment